Plasmodium vivax is the most geographically widespread cause of human malaria and is
responsible for the majority of cases outside of the African continent. While great progress …

The threat of widespread drug resistance to frontline antimalarials has renewed the urgency
for identifying inexpensive chemotherapeutic compounds that are effective against …

Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine (DHA-
PPQ), Cambodia swapped the first line artemisinin-based combination therapy (ACT) from …

High-throughput phenotypic screening of chemical libraries has resulted in the identification
of thousands of compounds with potent antimalarial activity, although in most cases, the …

The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium
phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical …

The development of new combinations of antimalarial drugs is urgently needed to prevent
the spread of parasites resistant to drugs in clinical use and contribute to the control and …

ABSTRACT DSM265 is a novel antimalarial drug in clinical development that acts as a
selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous phase 1b …

Plasmodium vivax chloroquine resistance has been documented in nearly every region
where this malaria-causing parasite is endemic. Unfortunately, P. vivax resistance …

Artefenomel and DSM265 are two new compounds that have been shown to be well
tolerated and effective when administered as monotherapy malaria treatment. This study …

Effective progression of candidate antimalarials is dependent on optimal dosing in clinical
studies, which is determined by a sound understanding of pharmacokinetics and …